Mobile

A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001101-10

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to evaluate the efficacy of Zometa in delaying disease progression, disease recurrence or death in patients with locally advanced, stage IIIA and IIIB NSCLC. The primary endpoint is progression free survival. Patients in the treatment arm will receive ZOMETA every 3-4 weeks. Patients in the control arm will not receive ZOMETA treatment until development of bone metastases.

Critère d'inclusion

  • Patients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases

Liens